Abstract
Introduction
Several hemodynamic changes occur in pregnancy to accommodate the required 48 increase in blood flow for sustenance of the fetoplacental unit. The renin-angiotensin 49 system (RAS) is activated in normal pregnancies to increase salt retention which 50 contributes to an increase in blood volume and compensatory increase in diastolic 51 preload and cardiac output (3, 6, 16) . Despite these increases in blood volume, normal maintains vascular tension at normal levels (10, 12, 23, 31) . This careful balance of pro-56 constrictive and pro-relaxation factors is essential for the maternal vasculature to adapt 57 and ensure adequate blood flow to the growing fetoplacental unit.
59
Preeclampsia (PE) is a hypertensive disorder of pregnancy characterized by vascular 60 dysfunction and abnormal RAS activation (10) (11) (12) 19) . In contrast to normal pregnant 61 women, PE women exhibit increased vasoconstrictive sensitivity to ANGII, resulting in a 62 decrease in vascular compliance and an increase in blood pressure (10, 12) . This loss 63 of protection from ANGII-induced vasoconstriction is associated with systemic increases 64 in reactive oxygen species (ROS), vasoconstrictive endothelin-1 (ET-1) and anti-65 angiogenic soluble FMS-like tyrosine kinase-1 (sFlt-1), which are markers of endothelial 66 dysfunction and PE severity in these patients (11, 15, 32) . Drugs such as angiotensin II 67 type I (AT1) receptor blockers and angiotensin converting enzyme (ACE) inhibitors are 68 contraindicated in pregnancy, however, a therapeutic agent that reduces ANGII 69 sensitivity in PE patients safely would be expected to alleviate hypertension in these 70 patients.
72
Autoantibodies to the angiotensin II (ANGII) type I receptor (AT1-AA) are increased in
73
PE patients compared to normal pregnant and their levels correlate with the severity of 74 PE and have been suggested as a mechanism whereby such hypersensitivity to ANGII 75 develops in PE (7, 21, 30, 38) . Infusion of AT1-AA into pregnant rats induces many of 76 the characteristics of PE, such as hypertension, sFlt-1, ET-1 and ROS, which are 77 implicated in the development of hypertension and IUGR in PE patients (5, 33 is important in evaluating the safety of Vitamin D in our AT1-AA and ANGII infused rats.
193
Neither AT1-AA nor ANGII infusion into pregnant rats significantly affected pup weights 194 in our study. Pup weights were also not changed in NP, AT1-AA-or ANGII-infused rats rats, however, VD3 had no effect. As shown in previous studies, AT1-AA infusion into pregnant rats (714.6±188.5 pg/ml) 219 increased circulating sFlt-1 levels compared to NP rats (93.9±12.1 pg/ml, P<0.05, 220 unpaired t-test and one-way ANOVA). [ Figure 2a] We assessed levels of an indicator of reactive oxygen species, 8-isoprostanes, in 251 plasma. AT1-AA-infused pregnant rats had increased isoprostane (1633±179 pg/ml, 252 P<0.05, unpaired t-test and one-way ANOVA) compared to NP rats (634±197 pg/ml)
253
[ Figure 2d ]. VD2 and VD3 supplementation in AT1-AA-infused rats reduced the 254 isoprostane levels (436±81 and 752±94 pg/ml, respectively, P<0.05, unpaired t-test and 255 one-way ANOVA). ANGII rats had significantly higher isoprostane levels compared to 256 NP (1505±233 pg/ml, P<0.05, unpaired t-test). However, they did not change in 257 ANGII+VD2 (1682±248 pg/ml) or ANGII+VD3 (1714±247 pg/ml). These data indicate 258 that although the extent to which isoprostanes were increased was similar in AT1-AA 259 and ANGII infused rats, the mechanism by which Vitamin D reduced isoprostanes was 260 specific to AT1-AA-induced mechanisms. ROS during pregnancy, it does not stimulate sFlt-1 and other PE features (5).
274
Therefore, ANGII infusion into pregnant rats was used as a model to study hypertension 275 during pregnancy without PE features, which would be comparable to gestational or 276 chronic hypertension in pregnancy. Therefore, the purpose of the present study was to and 27) . While the exact mechanism via which AT1-AA induces increases in 316 sFlt-1 levels remains unclear, these data demonstrate that Vitamin D can alter this 317 mechanism as a method to improve blood pressure during high levels of AT1-AA, as in 318 the case of PE. Importantly, and indicating the specificity for AT1-AA during PE, sFlt-1 is 319 not elevated in ANGII-induced hypertensive pregnant rats in this study.
321
ET-1 is a potent vasoconstrictor peptide and is increased in both human preeclamptic 322 patients and in rodent models of PE (1, 22, 29, 35) . ET-1 is induced in response to AT1 44 ). In our current study, we found that both ANGII and AT1-AA induced ET-1 in the renal cortex, most likely a mechanism 339 contributing to the hypertension in each model. VD2 decreased ET-1 in the renal cortex 340 in each model while VD3 seemed to have no effect. These data indicate that the AT1-341 dependent mechanism via which AT1-AA and ANGII activate ET-1 transcription in the 342 renal cortex is similar and, furthermore, that the mechanism via which VD2 and VD3 343 interact with that mechanism is also similar. In contrast, only AT1-AA stimulated 344 placental ET-1, and profoundly so, indicating an important difference between AT1-AA 345 and ANGII stimulated pathways during hypertensive pregnancy. Both VD2 and VD3 346 reduced placental ET-1 while only VD2 was able to significantly reduce UARI, which 347 indicates that reductions in both placental and renal cortex ET-1 production contributed 348 to reduce UARI in our AT1-AA infused rats. AA infusion into pregnant rats increased sFlt-1 and ET-1, whereas ANGII had no effect (a). Plasma sFlt-1 levels were significantly increased in AT1-AA infused rats. sFlt-1 was 571 significantly reduced in AT1-AA-infused rats treated with either VD2 or VD3. ANGII 572 infusion into pregnant rats did not alter sFlt-1 levels. VD2 did reduce sFlt-1 levels in 573 ANGII-infused rats but VD3 had no effect. Neither VD2 nor VD3 affected sFlt-1 levels in 574 NP rats (N: NP=7, NP+VD2=3, NP+VD3=4, ANGII=4, ANGII+VD2=4, ANGII+VD3=4, 
598
Figure 1 (a). Blood pressures, comparisons by unpaired t-test, on GD19 of NP, ANGIIand AT1-AA-infused rats treated with VD2 and VD3, (b). Pup weights, comparisons by unpaired t-test and one-way ANOVA, of NP, ANGII-and AT1-AAinfused rats treated with VD2 and VD3, (c). Placenta weights, comparisons by unpaired t-test, of NP, ANGII-and AT1-AA-infused rats treated with VD2 and VD3, (d). Placental efficiency, comparisons by unpaired t-test and one-way ANOVA, of NP, ANGII-and AT1-AA-infused rats treated with VD2 and VD3, (e). Uterine Artery Resistance Index (UARI), comparisons by unpaired t-test, on GD18 of NP, ANGII-and AT1-AA-infused rats treated with VD2 and VD 3. 
